155 related articles for article (PubMed ID: 34220523)
1. ABCB1 and ABCG2 Together Limit the Distribution of ABCB1/ABCG2 Substrates to the Human Retina and the
El Biali M; Karch R; Philippe C; Haslacher H; Tournier N; Hacker M; Zeitlinger M; Schmidl D; Langer O; Bauer M
Front Pharmacol; 2021; 12():698966. PubMed ID: 34220523
[TBL] [Abstract][Full Text] [Related]
2. Pilot PET Study to Assess the Functional Interplay Between ABCB1 and ABCG2 at the Human Blood-Brain Barrier.
Bauer M; Römermann K; Karch R; Wulkersdorfer B; Stanek J; Philippe C; Maier-Salamon A; Haslacher H; Jungbauer C; Wadsak W; Jäger W; Löscher W; Hacker M; Zeitlinger M; Langer O
Clin Pharmacol Ther; 2016 Aug; 100(2):131-41. PubMed ID: 26940368
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of ABCB1 and ABCG2 at the Mouse Blood-Brain Barrier with Marketed Drugs To Improve Brain Delivery of the Model ABCB1/ABCG2 Substrate [
Traxl A; Mairinger S; Filip T; Sauberer M; Stanek J; Poschner S; Jäger W; Zoufal V; Novarino G; Tournier N; Bauer M; Wanek T; Langer O
Mol Pharm; 2019 Mar; 16(3):1282-1293. PubMed ID: 30694684
[TBL] [Abstract][Full Text] [Related]
4. A Proof-of-Concept Study to Inhibit ABCG2- and ABCB1-Mediated Efflux Transport at the Human Blood-Brain Barrier.
Bauer M; Karch R; Wulkersdorfer B; Philippe C; Nics L; Klebermass EM; Weber M; Poschner S; Haslacher H; Jäger W; Tournier N; Wadsak W; Hacker M; Zeitlinger M; Langer O
J Nucl Med; 2019 Apr; 60(4):486-491. PubMed ID: 30237210
[TBL] [Abstract][Full Text] [Related]
5. Complete inhibition of ABCB1 and ABCG2 at the blood-brain barrier by co-infusion of erlotinib and tariquidar to improve brain delivery of the model ABCB1/ABCG2 substrate [
Tournier N; Goutal S; Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Caillé F; Breuil L; Stanek J; Freeman AF; Novarino G; Truillet C; Wanek T; Langer O
J Cereb Blood Flow Metab; 2021 Jul; 41(7):1634-1646. PubMed ID: 33081568
[TBL] [Abstract][Full Text] [Related]
6. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
[TBL] [Abstract][Full Text] [Related]
7. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [
Hernández Lozano I; Bauer M; Wulkersdorfer B; Traxl A; Philippe C; Weber M; Häusler S; Stieger B; Jäger W; Mairinger S; Wanek T; Hacker M; Zeitlinger M; Langer O
Mol Pharm; 2020 Jan; 17(1):316-326. PubMed ID: 31790256
[TBL] [Abstract][Full Text] [Related]
8. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
[TBL] [Abstract][Full Text] [Related]
9. Assessment of brain delivery of a model ABCB1/ABCG2 substrate in patients with non-contrast-enhancing brain tumors with positron emission tomography.
Wulkersdorfer B; Bauer M; Karch R; Stefanits H; Philippe C; Weber M; Czech T; Menet MC; Declèves X; Hainfellner JA; Preusser M; Hacker M; Zeitlinger M; Müller M; Langer O
EJNMMI Res; 2019 Dec; 9(1):110. PubMed ID: 31832814
[TBL] [Abstract][Full Text] [Related]
10. P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of
Auvity S; Caillé F; Marie S; Wimberley C; Bauer M; Langer O; Buvat I; Goutal S; Tournier N
J Nucl Med; 2018 Oct; 59(10):1609-1615. PubMed ID: 29748235
[TBL] [Abstract][Full Text] [Related]
11. Assessment of P-Glycoprotein Transport Activity at the Human Blood-Retina Barrier with (
Bauer M; Karch R; Tournier N; Cisternino S; Wadsak W; Hacker M; Marhofer P; Zeitlinger M; Langer O
J Nucl Med; 2017 Apr; 58(4):678-681. PubMed ID: 27738009
[TBL] [Abstract][Full Text] [Related]
12. Correlation between clinical response to sorafenib in hepatocellular carcinoma treatment and polymorphisms of P-glycoprotein (ABCB1) and of breast cancer resistance protein (ABCG2): monocentric study.
Tandia M; Mhiri A; Paule B; Saffroy R; Cailliez V; Noé G; Farinotti R; Bonhomme-Faivre L
Cancer Chemother Pharmacol; 2017 Apr; 79(4):759-766. PubMed ID: 28289864
[TBL] [Abstract][Full Text] [Related]
13. Effects of the ABCG2 and ABCB1 drug transporter polymorphisms on the pharmacokinetics of bicalutamide in humans.
Kim KA; Cha YJ; Lee HM; Joo HJ; Park JY
Clin Chim Acta; 2015 Jan; 438():7-11. PubMed ID: 25124867
[TBL] [Abstract][Full Text] [Related]
14. Molecular Imaging of ABCB1 and ABCG2 Inhibition at the Human Blood-Brain Barrier Using Elacridar and
Verheijen RB; Yaqub M; Sawicki E; van Tellingen O; Lammertsma AA; Nuijen B; Schellens JHM; Beijnen JH; Huitema ADR; Hendrikse NH; Steeghs N
J Nucl Med; 2018 Jun; 59(6):973-979. PubMed ID: 29175983
[TBL] [Abstract][Full Text] [Related]
15. Influence of germline variations in drug transporters ABCB1 and ABCG2 on intracerebral osimertinib efficacy in patients with non-small cell lung cancer.
Veerman GDM; Boosman RJ; Jebbink M; Oomen-de Hoop E; van der Wekken AJ; Bahce I; Hendriks LEL; Croes S; Steendam CMJ; de Jonge E; Koolen SLW; Steeghs N; van Schaik RHN; Smit EF; Dingemans AC; Huitema ADR; Mathijssen RHJ
EClinicalMedicine; 2023 May; 59():101955. PubMed ID: 37125403
[TBL] [Abstract][Full Text] [Related]
16. Assessing the Functional Redundancy between P-gp and BCRP in Controlling the Brain Distribution and Biliary Excretion of Dual Substrates with PET Imaging in Mice.
Hernández-Lozano I; Mairinger S; Traxl A; Sauberer M; Filip T; Stanek J; Kuntner C; Wanek T; Langer O
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452247
[TBL] [Abstract][Full Text] [Related]
17. Association of genotypes and haplotypes of multi-drug transporter genes ABCB1 and ABCG2 with clinical response to imatinib mesylate in chronic myeloid leukemia patients.
Au A; Aziz Baba A; Goh AS; Wahid Fadilah SA; Teh A; Rosline H; Ankathil R
Biomed Pharmacother; 2014 Apr; 68(3):343-9. PubMed ID: 24581936
[TBL] [Abstract][Full Text] [Related]
18. Effect of P-glycoprotein inhibition at the blood-brain barrier on brain distribution of (R)-[
Bauer M; Wulkersdorfer B; Karch R; Philippe C; Jäger W; Stanek J; Wadsak W; Hacker M; Zeitlinger M; Langer O
Br J Clin Pharmacol; 2017 Sep; 83(9):1991-1999. PubMed ID: 28401570
[TBL] [Abstract][Full Text] [Related]
19. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
[TBL] [Abstract][Full Text] [Related]
20.
Park JW; Chung H; Kim KA; Kim JM; Park IH; Lee S; Park JY
Front Pharmacol; 2021; 12():658039. PubMed ID: 33995081
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
